Co-CEO Doubles Down. $50M Says Bottom.
Second co-CEO buy in one day. Same $50M commitment, same $13.12 price. When two chiefs put $100M combined on the line at identical levels, they're signaling hard support. Healthcare's defensive momentum should cushion the downside, but all timeframes are selling. The RSI at 37 suggests oversold conditions, though the technical picture remains messy until we see some price confirmation above resistance.
The Filing
| Ticker | SMMT |
| Company | Summit Therapeutics Inc. |
| Insider | Mahkam Zanganeh, Co-Chief Executive Officer |
| Buy amount | $50.0M |
| Filing date | June 12, 2026 |
| Conviction | Favorable · 67/100 |
| Setup type | Oversold Bounce |
Ultimate members received this analysis in real time.